Amicus Therapeutics Announces First Quarter 2008 Financi...(/p ...)

Stock GAAP as

Non-GAAP Compensation Reported

Income Statement

Classifications:

Revenue $3,160 $3,160

Research and development (6,412) $(529) (6,941)

General and administrative (4,368) (818) (5,186)

Depreciation and

amortization (321) (321)

Interest income 1,702 1,702

Interest expense (70) (70)

(Provision for)/benefit

from income taxes (75) (75)

Summary:

Net loss: $(6,384) $ (1,347) $ (7,731)

Net loss per share - basic

and diluted: $(0.28) $(0.06) $(0.34)

Weighted average number

of shares outstanding: 22,412,689 22,412,689

Table 3

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended March 31, 2007

(Unaudited)

(In thousands, except share and per share amounts)

Change

in Fair Pre-

Value of ferred

Warrant Stock Stock

Non- Lia- Accre- Compen- GAAP as

GAAP bility tion sation Reported

Income Statement

Classifications:

Research and

development $(6,795) $- $- $(290
'/>"/>